<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023707</url>
  </required_header>
  <id_info>
    <org_study_id>2021136</org_study_id>
    <nct_id>NCT05023707</nct_id>
  </id_info>
  <brief_title>Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Pilot Study of the Safety and Efficacy of Anti-FLT3 Chimeric Antigen Receptor Engineered T-Cells in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huai'an Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective,open-label, phase1/2 study to evaluate the safety and efficacy of&#xD;
      anti-FLT3 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment&#xD;
      of FLT3 positive relapsed or refractory acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will receive infusion of anti-FLT3 CAR T-cells targeting FLT3 to evaluate the&#xD;
      safety and efficacy of anti-FLT3 CAR T-Cells in relapsed or refractory acute myeloid&#xD;
      leukemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 19, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events are evaluated with CTCAE V5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>ORR includes CR, CRi, MLFS and PR. Complete remission (CR)：Bone marrow blasts &lt;5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0x 10^9/L; platelet count &gt;100x10^9/L. CR with incomplete hematologic recovery (CRi)：All CR criteria except for residual neutropenia (&lt;1.0 x 109/L) or thrombocytopenia (&lt;100 x 109/L). Morphologic leukemia-free state (MLFS): Bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required. Partial remission (PR): All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>2 years</time_frame>
    <description>time from enrollment to the date of primary refractory disease, or relapse from CR or CRi, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse(CIR)</measure>
    <time_frame>2 years</time_frame>
    <description>time from the date of achievement of a remission until the date of relapse</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>CAR-T infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FLT3 positive relapsed or refractory acute myeloid leukemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-FLT3 CAR-T</intervention_name>
    <description>Single intravenous infusion of anti-FLT3 CAR-T cells</description>
    <arm_group_label>CAR-T infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  FLT3 positive relapsed/refractory acute myeloid leukemia&#xD;
&#xD;
          -  Age 16-65 years.&#xD;
&#xD;
          -  Left ventricular ejection fractions ≥ 0.5 by echocardiography&#xD;
&#xD;
          -  Creatinine &lt; 1.5x upper limit of normal.&#xD;
&#xD;
          -  Aspartate aminotransferase/aspartate aminotransferase ≤ 2.5x upper limit of normal&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5x upper limit of normal&#xD;
&#xD;
          -  Karnofsky performance status ≥ 60&#xD;
&#xD;
          -  Expected survival time ≥ 3 months (according to investigator's judgement)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients are pregnant or lactating&#xD;
&#xD;
          -  Uncontrolled active infection&#xD;
&#xD;
          -  Grade III/IV cardiovascular disability according to the New York Heart&#xD;
&#xD;
          -  Association Classification&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Patients with HIV infection&#xD;
&#xD;
          -  Patients with a history of seizure&#xD;
&#xD;
          -  Patients with other contraindications considered unsuitable for participation in this&#xD;
             study (according to investigator's judgement)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaowen Tang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaowen Tang, Ph.D</last_name>
    <phone>(0086)51267781856</phone>
    <email>xwtang1020@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Yang, Ph.D</last_name>
    <phone>(0086)18896802149</phone>
    <email>huimin.meng@persongen.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaowen Tang, Ph.D</last_name>
      <phone>86-512677801856</phone>
      <email>xwtang1020@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FLT3,CAR-T,AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

